<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00656032</url>
  </required_header>
  <id_info>
    <org_study_id>080074</org_study_id>
    <nct_id>NCT00656032</nct_id>
  </id_info>
  <brief_title>Vitamin D, Insulin Resistance and Inflammation in ESRD</brief_title>
  <official_title>Vitamin D, Insulin Resistance and Inflammation in ESRD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The broad goal of this study is to understand the mechanisms by which Vitamin D receptor
      activation leads to changes in insulin signaling in advanced uremia. We hypothesize that
      1,25-Dihydroxyvitamin D3 deficiency due to advanced chronic kidney disease leads to insulin
      resistance and that administration of a vitamin D3 analog will restore insulin sensitivity in
      End Stage Renal Disease patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>An improvement in insulin sensitivity</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>A change in insulin signaling</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A decrease in concentration of plasma pro-inflammatory cytokines</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>End Stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SOC medication for treatment of renal osteodystrophy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>alternate SOC medication for treatment of renal osteodystrophy</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>paricalcitol</intervention_name>
    <description>1 to 20 micrograms administered via IV; every other day, 3 days per week, for 8 weeks</description>
    <arm_group_label>1</arm_group_label>
    <other_name>zemplar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>cinacalcet</intervention_name>
    <description>0 to 180 mg administered orally every day for either 8 weeks or 16 weeks</description>
    <arm_group_label>2</arm_group_label>
    <other_name>sensipar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  CKD and receiving hemodialysis for ≥ 3months

          -  Kt/V ≥ 1.2

          -  ≥ 18 years of age

          -  Medically stable

          -  AVF or PTFE dialysis access

          -  No acute inflammatory disease within 4 weeks prior to the study

          -  On stable dose of Paricalcitol for 4 weeks prior to the study

          -  iPTH value between 150 - 1500 within the past 3 months

          -  Ca &lt; 10.5

          -  PO4 &lt; 10

        Exclusion Criteria:

          -  Pregnancy

          -  Intolerance to the study medication

          -  Severe, unstable, active, or chronic inflammatory disease (active infection, active
             connective tissue disorder, active cancer, HIV, liver disease)

          -  Type 1 Diabetes mellitus

          -  Uncontrolled Type 2 Diabetes mellitus (HbA1c &gt; 10)

          -  Hospitalization within 1 month prior to the study

          -  Malfunctioning arterial-venous vascular access (recirculation and/or blood flow &lt; 250
             ml/min)

          -  Presence of hemodialysis catheter

          -  Patients receiving steroids and/or other immunosuppressive agents (&gt; 10 mg prednisone
             qd)

          -  BMI &lt; 25 and &gt; 45
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alp Ikizler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2008</study_first_submitted>
  <study_first_submitted_qc>April 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2008</study_first_posted>
  <last_update_submitted>January 9, 2012</last_update_submitted>
  <last_update_submitted_qc>January 9, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 11, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University</investigator_affiliation>
    <investigator_full_name>Alp Ikizler</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>insulin resistance</keyword>
  <keyword>end stage renal disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Cinacalcet Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

